**Supplementary Table S1.** Prospective randomized clinical trials with PD1 inhibitors in esophageal, gastro-esophageal and gastric cancer.

| Trial (Asian population, %) | N/ Location | Schedule | PFS HR (95% CI) | mPFS (E/C), months | 2-y PFSR% (E/C) | OS HR (95% CI) | mOS (E/C), months | 3-y OSR% (E/C) | ESMO-MCBS PFS/OS |
|---|---|---|---|---|---|---|---|---|---|
| CheckMate 649 (25%) | 1581 (E,EG,G) | NIVO+CHT vs. CHT | 0.79 (0.71–0.89) | 7.7 (7–9.2) vs. 6.9 (5.6–6.9) | 16 vs. 10 | 0.79 (0.71–0.88) | 13.7 (6.7–19.1) vs. 11.6 (5.8–16.1) | 17 vs. 10 | 1/2 |
| ATTRACTION -04 (100%) | 724 (EG/G) | NIVO+CHT vs. CHT | 0.68 (0.51–0.90) | 10.4 (8.4 14.7) vs. 8.3 (6.9–9.4) | 30 vs. 20 | 0.90 (0.7–1.1) | 17.4 (15.6–20.8) vs. 17.1 (15.1–19.6) | 22 vs. 21 | 2/1 |
| JAVELIN 100 (23%) | 805 (EG/G) | AVE vs. CHT* | – | – | – | 0.91 (0.74–1.11) | 10.4 (9.1–12.0) vs. 10.9 (9.6–12.4) | 22 vs. 15 | NE/1 |
| RATIONALE-305 (75%) | 997 (EG/G) | TISLE+CHT vs. CHT | 0.67 (0.55–0.83) | 6.9 (5.7–7.2) vs. 6.2 (5.6–6.9) | 17 vs. 9 | 0.80 (0.7–0.9) | 15.0 (13.6–16.5) vs. 12.9 (12.1–14.1) | 20 vs. 15 | 2/2 |
| KEYNOTE-062 (25%) | 507** (EG/G) | PEM+CHT vs. CHT | 0.84 (0.70–1.02) | 6.9 vs. 6.4 | 15 vs. 8 | 0.85 (0.70–1.03) | 12.5 vs. 11.1 | 18 vs. 10 | 1/1 |
| KEYNOTE-859 (34%) | 1579 (EG/G) | PEM+CHT vs. CHT | 0.76 (0.67–0.85) | 6.9 (6.3–7.2) vs. 5.6 (5.5–5.7) | 18 vs. 9 | 0.78 (0.70–0.87) | 12.9 (11.9–14.0) vs. 11.5 (10.6–12.1) | 21 vs. 12 | 1/2 |
| KEYNOTE-590 (54%) | 1020 (E) | PEM+CHT vs. CHT | 0.65 (0.55–0.76) | 6.3 vs. 5.8 | 10 vs. 0 | 0.73 (0.62–0.86) | 12.4 vs. 9.8 | 25 vs. 18 | 2/3 |
| ORIENT-16 (100%) | 650 (EG/G) | SINTI+CHT vs. CHT | 0.64 (0.52–0.77) | 7.1 vs. 5.7 | 20 vs. 10 | 0.77 (0.63–0.94) | 15.2 vs. 12.3 | 37 vs. 22* | 2/2 |

mOS, median overall survival; mPFS, median progression-free survival; OSR, overall survival rate. * % were extrapolated from Kaplan-Meier curves.